Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Lee's Pharm Acquires China Rights to GC Pharma Anticoagulant

publication date: Feb 14, 2018

Lee's Pharm of Hong Kong in-licensed Greater China rights to an investigational anticoagulant being developed by Korea's GC Pharma (formerly known as Green Cross). Lee's will also develop the anticoagulant, an oral Factor Xa inhibitor, in other Southeast Asian countries. GC Pharma will receive an upfront payment along with milestones and royalties, though specific details were not disclosed. Lee's is active in China's anticoagulant space, with one marketed product and several others in development. More details....

Stock Symbols: (HK: 0950) (KRX: 006280) 

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020